1. Scrip
  2. >>Business

ESSA Pharma Will Fit Into Xtandi, Zytiga Prostate Cancer Treatment Gaps

 
• By Lucie Ellis-Taitt

Emerging Company Profile: ESSA Pharma, a publically traded cancer R&D company, believes it has the answer to drug resistance in patients treated with best-selling cancer therapies Xtandi and Zytiga – as it targets last-line patients with a prostate cancer therapy based on a new mechanism of action.

ESSA Pharma Inc. is the first company to enter the clinic with a drug program based on a new mechanism of action targeting the N-terminal domain of androgen receptors in metastatic castration-resistant prostate cancer patients.

ESSA Pharma, founded in 2009 in Vancouver, Canada, went public last year on the NASDAQ capital market after relocating some of its business to Texas, US, in order to receive a financing grant from the Cancer Prevention and Research

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Start-Ups & SMEs

More from Business